July 3, 2019

Saqib Islam
Chief Executive Officer
SpringWorks Therapeutics, Inc.
100 Washington Blvd
Stamford, CT 06902

       Re: SpringWorks Therapeutics, Inc.
           Draft Registration Statement on Form S-1
           Submitted June 7, 2019
           CIK No. 0001773427

Dear Mr. Islam:

       We have reviewed your draft registration statement and have the
following comments. In
some of our comments, we may ask you to provide us with information so we may
understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional

Draft Registration Statement on Form S-1

Prospectus summary
Overview, page 1

1.     To the extent known, please elaborate on the expected timeline for the
DeFi trail,
       including what kind of update you expect to provide in 2020 and how long
you expect the
       trial to last.
Our portfolio, page 2

2.     Please disclose what are the "select international markets" for your
Nirogacestat and PD-
       0325901 product candidates.
 Saqib Islam
SpringWorks Therapeutics, Inc.
July 3, 2019
Page 2
Implications of being an emerging growth company, page 6

3.       Please provide us with copies of all written communications, as
defined in Rule 405 under
         the Securities Act, that you, or anyone authorized to do so on your
behalf, present to
         potential investors in reliance on Section 5(d) of the Securities Act,
whether or not they
         retain copies of the communications.
Use of proceeds, page 79

4.       We note your disclosure that you intend to use the proceeds of this
offering to further
         the development of your pipeline projects, further develop any
additional product
         candidates that you elect to develop alone or in combination with a
partner, expand your
         internal product development and clinical capabilities, and for
working capital and
         other general corporate purposes. Please specify how far in the
development of your
         pipeline projects you expect to reach with the proceeds of the
offering. If any material
         amounts of other funds are necessary to accomplish the specified
purposes, state the
         amounts and sources of other funds needed for each specified purpose
and the sources.
         Refer to Instruction 3 to Item 504 of Regulation S-K.
Management's Discussion and Analysis of Financial Conditions and Results of
Critical Accounting Policies and Estimates
Determination of the Fair Value of Equity-Based Awards, page 100

5.       Once you have an estimated offering price or range, please explain to
us how you
         determined the fair value of the common stock/units underlying your
equity issuances and
         the reasons for any differences between the recent valuations of your
common stock/units
         leading up to the IPO and the estimated offering price. This
information will help facilitate
         our review of your accounting for equity issuances including stock
compensation and
         beneficial conversion features.
Phase 2 clinical trial (WI180798), page 113

6.       We note your disclosure on page 113 that the "[r]esponse evaluation
was not possible for
         patient #14." Please disclose why the response evaluation was not
BGB-3245 in Genetically Defined BRAF-Mutant Solid Tumors, page 126

7.      Please disclose the company's equity ownership percentage in MapKure as
well as its
FirstName LastNameSaqib Islam
        level of board representation. Please also file the service agreement
and any material joint
Comapany NameSpringWorks Therapeutics, Inc.
        venture agreement as exhibits to the registration statement or tell us
why you are not
July 3, required to 2 so.
        2019 Page do
FirstName LastName
 Saqib Islam
FirstName LastNameSaqib Islam
SpringWorks Therapeutics, Inc.
Comapany NameSpringWorks Therapeutics, Inc.
July 3, 2019
Page 3
July 3, 2019 Page 3
FirstName LastName
License and collaboration agreements, page 127

8.       Please disclose the termination notice periods for the Nirogacestat
and PD-0325901
         license agreements.

9.       Please explain what you mean by "potentially registrational" trials,
as referenced
         throughout the prospectus.
10.      Please revise throughout to remove any inference regarding regulatory
approval or the
         safety and efficacy of your product candidates. We note, by way of
example, the
         statement regarding the potential to offer a "best-in-class"
combination of "tolerability and
         efficacy" on page 1 and elsewhere in the prospectus.
       You may contact Christine Torney at (202) 551-3652 or Angela Connell,
Branch Chief, at (202) 551-3426 if you have questions regarding comments on the
statements and related matters. Please contact Tonya K. Aldave at (202)
551-3601 or Justin
Dobbie, Legal Branch Chief, at (202) 551-3469 with any other questions.


                                                               Division of
Corporation Finance
                                                               Office of
Healthcare & Insurance
cc:      Kingsley Taft, Esq.